Actuate therapeutics announces closing of initial public offering

Chicago and fort worth, texas, aug. 14, 2024 (globe newswire) -- actuate therapeutics, inc. (nasdaq: actu) (the “company”), a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers, announced today the closing of its previously announced initial public offering of 2,800,000 shares of its common stock, at a price of $8.00 per share to the public for a total of $22,400,000 of gross proceeds to the company, before deducting underwriting discounts and offering expenses (the “offering”). in addition, the company has granted a 30-day option to the underwriters to purchase up to 420,000 additional shares, representing 15% of the shares sold in the offering, solely to cover over-allotments, if any, at the initial public offering price, less the underwriting discounts and commissions. all of the shares are being offered by the company. the shares began trading on august 13, 2024 on the nasdaq global market under the symbol “actu.”
ACTU Ratings Summary
ACTU Quant Ranking